Context

After 10 years of being successfully listed on Euronext Brussels, Ablynx pursues a USD 230m NASDAQ listing off the back of successful phase III results in Capla, furthering its transformation into a leading European biopharma company.

Ablynx is a unique, versatile and validated Nanobodytechnology platform combining the key advantages of mAbs and small molecules; with the proven capability to generate multi-functional molecules, and the ability to utilize targeted routes of drug administration and modulate half-life.

It has a broad and diversified portfolio with more than 45 wholly-owned and partnered programmes (8 in clinical development).

It has developped Caplacizumab, (wholly-owned): Compelling Phase III data in the ~€800M1p.a. orphan a TTP market potentially supporting regulatory approval in the near-term in Europe and the U.S.A
Additionally, ALX-0171, (also wholly-owned): a potential breakthrough in the €1Bn+ RSV market, pioneering pulmonary delivery of biologics.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single - domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small - molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology,immuno - oncology, oncology and respiratory disease. Ablynx has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals.

Discover Ablynx

Hervé Ronin

Investment Banking

Jean de Pracomtal

Investment Banking

Pierre Kiecolt-Wahl

Investment Banking

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center